New Hope for Management of Tuberous Sclerosis. Anil Kapoor, MD, FRCSC Professor of Surgery (Urology), McMaster University Hamilton, Ontario
|
|
- Anastasia Shields
- 6 years ago
- Views:
Transcription
1 New Hope for Management of Tuberous Sclerosis Anil Kapoor, MD, FRCSC Professor of Surgery (Urology), McMaster University Hamilton, Ontario
2 Tuberous Sclerosis Complex (TSC) Incidence 1:6000 Genetic disorder Mutations in genes TSC1 and TSC2 Affects 1-2 million people worldwide Approximately 5,000 in Canada Multi-organ benign tumours throughout the body Franz DN, et al. Neuropediatrics 2010;41:
3 The Role of the mtor Pathway in TSC Loss of TSC1/TSC2 in the mtor pathway defines TSC The tuberous sclerosis complex (TSC1/TSC2) are tumor suppressor proteins Inactivation of TSC1 or TSC2 leads to increased mtor activity Crino PB et al. N Engl J Med. 2006;355: ; Paul E et al. N Engl J Med. 2008;358: MDL037E
4 TSC Affects Multiple Organ Systems Neurologic Epilepsy / infantile spasms Brain tumours Cortical tubers SENs SEGA Renal Angiomyolipomas Cysts Cardiopulmonary Cardiac rhabdomyomas Lymphangioleiomyomatosis (LAM) Skin Facial angiofibromas Ash leaf spots Shagreen patches Ungual fibromas Ocular Retinal lesions Developmental/ Behavioral Problems Cognitive dysfunctional Autism spectrum disorder ADHD Anxiety SENs: subependymal nodules; SEGA: subependymal giant-cell astrocytoma; ADHD: Attention-deficit hyperactivity disorder Crino PB, et al. N Engl J Med 2006;355: ; Leung AK, et al. J Pediatr Health Care. 2007;21:
5 TSC Affects Multiple Organ Systems 1,2 Neurologic Epilepsy 90% Infantile seizures 20-30% Brain tumors - Cortical tubers 90 % - SENs 95% - SEGAs 6-19% Collections of dysmorphic neurons, large astrocytes, and giant cells 1,2 Epilepsy occurs in over 90% of patients and is associated with the presence of cortical tubers 2 SEN, subependymal nodule; SEGA: subependymal giant cell astrocytoma 1. Crino. N Engl J Med 2006;355: ; 2. Curatolo. Eur J Paediatr Neurol. 2002;6: MDL037E
6 TSC Affects Multiple Organ Systems 1,2 Neurologic Epilepsy 90% Infantile seizures 20-30% Brain tumors - Cortical tubers 90 % - SENs 95% - SEGAs 6-19% Numerous SENs distributed on the wall of the lateral ventricles SEGA, subependymal giant-cell astrocytoma; SEN, subependymal nodule Benign tumors, develop along ependymal lining of the lateral ventricles of the brain, proximal to the foramen of Monro 1,3 SENs usually remain dormant and do not cause symptoms Some SENs may increase in size to become SEGAs 1.Crino. N Engl J Med 2006;355: ; 2. Curatolo. Eur J Paediatr Neurol. 2002;6:15-23; 3.Yates, et al. Eur J Hum Genet 2006;14: MDL037E
7 TSC Affects Multiple Organ Systems 1,2 Neurologic Epilepsy 90% Infantile seizures 20-30% Brain tumors - Cortical tubers 90 % - SENs 95% - SEGAs 6-19% A large SEGA along the midline of the brain near the foramen of Monro SEGA, subependymal giant-cell astrocytoma; SEN, subependymal nodule SEGAs are well circumscribed, slowgrowing, low-grade tumors 3 Can obstruct the CSF circulation, leading to hydrocephalus Current intervention options: Surgical resection, if feasible Shunt implantation 1. Crino. N Engl J Med 2006;355: ; 2. Leung. J Pediatr Health Care. 2007; 21: ; 3. Buccoliero, et al. Neuropathology 2009;29: MDL037E
8 TSC Affects Multiple Organ Systems 1,2 Angiomyolipoma Slow growing, bilateral kidney tumors Complications due to mass effect: hemorrage or rupture of blood vessels feeding the lestion, destruction of adjacent renal tissue, risk of hypertension/renal failure Renal Angiomyolipomas (AML) 55-75% 1. Crino. N Engl J Med 2006;355: ; 2. Leung. J Pediatr Health Care. 2007; 21: MDL037E
9 TSC Affects Multiple Organ Systems 1,2 Cardiac rhabdomyoma Present in 50-70% infants with TSC Usually detected in utero or during the first year of life Often regresses/disappears later in life Although benign, position within critical areas in the heart may lead to lethal arrhythmias and heart failure Renal Angiomyolipomas 55-75% Cardiopulmonary Cardiac rhabdomyomas 33-48% 1. Crino. N Engl J Med 2006;355: ; 2. Leung. J Pediatr Health Care. 2007; 21: MDL037E
10 TSC Affects Multiple Organ Systems 1,2 LAM Progressive lung disease Occurs in 30-40% of women with TSC Infiltration of LAM smooth muscle cells and cystic destruction of the lung Renal Angiomyolipomas 55-75% Cardiopulmonary Cardiac rhabdomyomas 33-48% Lymphangioleiomyomatosis 26-39% Ocular Retinal lesions 40-50% 1. Crino. N Engl J Med 2006;355: ; 2. Leung. J Pediatr Health Care. 2007; 21: MDL037E
11 TSC Affects Multiple Organ Systems 1,2 Skin Facial angiofibromas Ash leaf spots Shagreen patches Ungual fibromas Developmental/ Behavioral Problems Cognitive dysfunction Autism spectrum disorder ADHD Anxiety ADHD, Attention Deficit Hyperactivity Disorder 1. Crino. N Engl J Med 2006;355: ; 2. Leung. J Pediatr Health Care. 2007; 21: MDL037E
12 Other Effects of TSC Ocular Retinal lesions: 40-50% Developmental/ Behavioral Problems Cognitive dysfunction Autism spectrum disorder ADHD Anxiety Crino PB, et al. N Engl J Med 2006;355: ; Leung AK, et al. J Pediatr Health Care 2007;21:
13 A Patient s Journey with TSC Prenatal < 1 year 1 5 yrs 5 18 yrs > 18 yrs Geneticists OB/GYN Cardiologist Neurologist Dermatologist Opthamologist Nephrologist/ Urologist Pulmonologist Rhabdomyomas Cortical tubers Subependymal nodules (SENs) Subependymal giant cell astrocytomas (SEGAs) Dermatologic manifestation Angiomyolipomas Retinal hamartomas LAM: lymphangioleiomyomatosis LAM Franz, et al. J Child Neurol 2004;19:690-8.; Isaacs. Am J Perinatol 2009;26:755-60; Park, et al. Acta Neuropathol 1997;94:180-6; Adriaensen, et al. Eur J Neurol 2009;16:691-6; Sweeney, et al. Adv Dermatol 2004;20:117-35; Roach, et al. J Child Neurol 2004;19:643-9; Sparagana, et al. Curr Opin Neurol 2000;13:
14 2012 Clinical Diagnostic Criteria for TSC Major features 1 Northrup H, et al. Pediatr Neurol 2013;49: Hypomelanotic macules ( 3, at least 5 mm in diameter) Minor features 1 Confetti skin lesions 2 Angiofibromas ( 3) or fibrous cephalic plaque 2 Dental enamel pits ( 3) 3 Ungual fibromas ( 2) 3 Intraoral fibromas ( 2) 4 Shagreen patch 4 Retinal achromic patch 5 Multiple retinal hamartomas 5 Multiple renal cysts 6 Cortical dysplasias* 6 Nonrenal hamartomas 7 Subependymal nodules 8 Subependymal giant cell astrocytomas 9 Cardiac rhabdomyoma 10 Lymphangioleiomyomatosis (LAM)** 11 Angiomyolipomas ( 2)** * Includes tubers and cerebral white matter radial migration lines. **A combination of the two major features LAM and angiomyolipomas without other features does not meet criteria for a definite diagnosis Definite Diagnosis 2 major features or 1 major feature + 2 minor features Possible Diagnosis 1 major feature or 2 minor features 14
15 2012 Genetic Diagnostic Criteria for TSC Either a TSC1 or TSC2 pathogenic mutation is sufficient for a definite diagnosis of TSC. A pathogenic mutation is a: mutation that clearly inactivates the function of TSC1 or TSC2 protein (e.g., out-of-frame indel or nonsense mutation) mutation that prevents protein synthesis (e.g., large genomic deletion) missense mutation whose effect on protein function has been established by functional assessment Other TSC1 or TSC2 variants whose effect on function is less certain do not meet these criteria, and are not sufficient to make a definite diagnosis of TSC. Genetics-based diagnosis even in the absence of clinical signs would facilitate appropriate monitoring of the genetically diagnosed individual throughout his/her lifetime It is noteworthy that 10-25% of individuals with TSC have no mutation identified by conventional genetic testing, and a normal result does not exclude TSC or have any effect on the use of Clinical Diagnostic Criteria to diagnose TSC Northrup H, et al. Pediatr Neurol 2013;49:
16 Diagnostic Recommendations Newly Diagnosed or Suspected TSC Genetics: Genetic testing when TSC diagnosis cannot be confirmed clinically Brain: Brain MRI to assess presence of tubers, SEN, migrational defects, SEGA Evaluate TSC-associated neurocognitive and behavioral disorder (TAND) During infancy, educate patients to recognize infantile spasms Baseline routine EEG: if abnormal, follow up with 24-hour video EEG Heart: Fetal ECG, when rhabdomyomas are identified via prenatal ultrasound Pediatric patients: obtain ECG, especially if <3 years All ages: obtain ECG to assess underlying conduction defects Kidney: MRI of abdomen, Screen for hypertension, Evaluate renal function by determination of GFR Lung: Females >18 yrs: Baseline pulmonary function tests; HRCT, even if asymptomatic Adult males: Undergo testing if symptomatic Skin/Teeth/Eye: Perform complete and detailed exams 14MDL099E
17 2012 TSC Surveillance Recommendations Already Diagnosed with Definite or Possible TSC CNS/Brain Brain MRI,1-3 years in asymptomatic patients <25 years Screen for TAND symptoms at least annually MRI: magnetic resonance EEG with known/suspected seizure activity, as clinically needed imaging; TAND: TSC-associated Eyes and Teeth neuropsychiatric disorders; Ophthalmology examination: annual EEG: electroencephalograph; Detailed dental examination: every 6 months HR-CT: high-resolution computed tomography; Panoramic radiographs of teeth if 7 years PFTs: pulmonary function tests Lung Every visit: clinical screening for symptoms No lung cysts: HR-CT every 5-10 years Lung cysts: HR-CT every 2-3 years, annual PFTs Krueger DA, et al. Pediatr Neurol 2013;49:
18 2012 TSC Surveillance Recommendations (cont d) Already Diagnosed with Definite or Possible TSC Heart Pediatric: Echocardiogram every 1-3 years if asymptomatic, more frequent/advanced assessment if symptomatic All ages: ECG every 3-5 years if asymptomatic, more frequent/advanced assessment if symptomatic ECG: electrocardiogram; MRI: magnetic resonance imaging; BP: blood pressure; GFR: glomerular filtration rate Kidney Skin MRI of abdomen every 1-3 years Attention to vascularity and presence of aneurysm BP and renal function (including GFR) at least annually Detailed dermatological exam (annual) Krueger DA, et al. Pediatr Neurol 2013;49:
19 MRI, CT or Ultrasound for Angiomyolipoma Screening? Typical fat-containing angiomyolipomas: are hyperechogenic on ultrasound; have low attenuation values on CT; appear as bright T1-weighted images, dark on T2-weighted images with fat saturation, and intermediate on T2-weighted images. MRI is modality of choice for detection of kidney and liver angiomyolipomas in TSC Rationale: CT or ultrasound may sometimes miss fat-poor angiomyolipomas; also CT associated with radiation exposure and nephrotoxicity If MRI is not readily available, CT or U/S can be used in the interim before MRI 19
20 Management of Angiomyolipomas in TSC First-line therapy: mtor inhibitor for asymptomatic, growing angiomyolipoma > 3 cm Embolization followed by corticosteroids for hemorrhage Nephrectomy to be avoided Second-line therapy: Selective embolization or kidney-sparing resection Krueger DA, et al. Pediatr Neurol 2013;49: Remember Surveillance: MRI of abdomen every 1-3 years Attention to vascularity and presence of aneurysm BP and renal function (including GFR) at least annually 20
21 Angiomyolipomas May be TSC-Associated or Sporadic Angiomyolipomas that occur in patients with no other clinical features of TSC are called sporadic Account for 80% of all angiomyolipomas Usually solitary and occur almost exclusively in women in their 40s Angiomyolipomas may be associated with retroperitoneal bleeding and impingement of the kidneys and other vital organs, impairing their function Blute ML, et al. J Urol 1988;139:20-24; Nelson CP, et al. J Urol 2002;168: El-Hashemite N, et al. Lancet 2003;361:1348-9; Smolarek TA, et al. Am J Hum Genet 1998;62:810-5; Avila NA, et al. Radiology 2007;242:
22 Characteristics of TSC-Associated vs. Sporadic Angiomyolipomas TSC-associated Angiomyolipoma Sporadic Angiomyolipoma P-value (Chi-square test) Mean age (years) Tumour diameter (cm) % multiple tumours < % at presentation: Symptomatic Acute hemorrhage < Nelson CP, et al. J Urol 2002;168:
23 RANDOMISATION (2:1) EXIST-2: Phase 3, Multicenter, Placebo-Controlled Study in Angiomyolipoma (NCT ) Eligibility Criteria (N=118) Age 18 yrs TSC (per modified Gomez criteria) or sporadic LAM (biopsy-proven or compatible chest CT scan) 1 AML lesion 3 cm in longest diameter using CT/MRI No requirement for AMLrelated surgery No AML-related bleeding or embolization in last 6 months Oral everolimus 10 mg once daily b (n=79) Crossover allowed at AML progression c Placebo b (n=39) Treatment until AML progression or unacceptable toxicity Stratified by (i) TSC and EIAED use versus (ii) TSC and no EIAED versus (iii) sporadic LAM ClinicalTrials.gov identifier NCT EIAED = enzyme inducing antiepileptic drug. Accrual between 08-May-2009 and 30-Dec a One patient was later found to not have renal AML b Dose adjusted based on toxicity. c AML progression by central review or occurrence of AE of AML-related bleeding grade 2 or worse Bissler JJ et al. Lancet 2013; 381: ; Bissler JJ. Pharmacokinetics/Pharmacodynamics of Everolimus in Patients With Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis. Presented at: International TSC Conference; September 6-9, 2012; Naples, Italy; Franz DN. The Effect of Everolimus, an Oral mtor Inhibitor, on Angiogenic Biomarkers in Patients With Tuberous Sclerosis Complex. Presented at: International TSC Conference; September 6-9, 2012; 13SOL017E Naples, Italy Jozwiak S. The Effect of Everolimus Therapy on Skin Lesions in Patients With Tuberous Sclerosis Complex: Results From the EXIST-1 and EXIST-2 Trials. Presented at: International TSC Conference; September 6-9, 2012; Naples, Italy.
24 EXIST-2: Baseline Demographics Everolimus n = 79 Placebo n = 39 Age, yrs, median (range) 32.0 ( ) 29.0 ( ) Age category, yrs, n (%) <30 35 (44.3) 20 (51.3) (55.7) 19 (48.7) Gender, n (%) Male 27 (34.2) 13 (33.3) Female 52 (65.8) 26 (66.7) Race, n (%) Caucasian 71 (89.9) 34 (87.2) Asian 7 (8.9) 4 (10.3) Other 1 (1.3) 1 (2.6) EXIST-2; NCT Bissler JJ et al. Lancet 2013; 381: Kingswood et al. International TSC Research Conference SOL017E
25 EXIST-2: Baseline Disease Characteristics Characteristic, n (%) Everolimus n = 79 Placebo n = 39 Diagnosis of TSC a 77 (97.5) 36 (92.3) Diagnosis of Sporadic LAM 2 (2.5) 3 (7.7) Diagnosis of LAM 22 (27.8) 7 (17.9) 1 skin lesion b, % 77 (97.5) 37 (94.9) Presence of SEGA c, % 43 (54.4) 14 (35.9) Previous AML treatment, % Surgery/invasive procedure 31 (39.2) 15 (38.5) Renal embolization 19 (24.1) 9 (23.1) Medication 0 0 EIAED = enzyme inducing antiepileptic drug. a All patients diagnosed with TSC had 2 major features of TSC present. b Based on patients having skin lesion photos at baseline, not based on the modified Gomez criteria. c Based on the major feature of SEGA in the modified Gomez criteria being ticked yes. EXIST-2; NCT Bissler JJ et al. Lancet 2013; 381: Kingswood et al. International TSC Research Conference SOL017E
26 EXIST-2: AML Response Rate Response, n (%) Primary analysis AML response rate a [95% CI] Everolimus n = (41.8) [30.8, 53.4] P-value b < Difference % (95% CI) 41.8 (23.5, 58.4) Best overall AML response Placebo n = 39 0 [0.0, 9.0] Response 33 (41.8) 0 Stable disease 32 (40.5) 31 (79.5) Progression 1 (1.3) 2 (5.1) Not evaluable 13 (16.5) 6 (15.4) 90 day update: At data cut-off date Oct 14, 2011, the angiomyolipoma response rate was 45.6% (95% CI, 34.3%-57.2%) for the everolimus arm and 0% (95% CI, 0.0%-9.0%) for the placebo arm, which translates to a clinically significant difference of 45.6% (95% CI, 27.5%-61.8%). a By central review; b P-value is obtained from the one sided exact Cochran-Mantel Haenszel test, stratified by the modified stratification factor (use of EIAED vs. non-use of EIAED) EXIST-2; NCT Bissler JJ et al. Lancet 2013; 381: Bissler JJ et al International Research Conference on TSC and Related Disorders: Molecules to Medicines; June 20-23, 2013; Washington DC, USA 13SOL017E
27 EXIST-2: AML Target Lesion Response Over Time Efficacy 42% showed 50% in AML volume (sum of all target lesions) vs 0% in placebo at 12 weeks 80% showed 30% in primary tumor size at 24 weeks 55% showed 50% in primary tumor size at 24 weeks No patient required embolization or surgery Placebo* Everolimus Placebo* Everolimus 13SOL017E
28 EXIST-2 Adverse Events by Preferred Term and Year of Emergence (>10% of Patients) a Everolimus Adverse Event, n (%) 12 Months n = Months n = Months n = Months n = 18 Stomatitis 46 (41.1) 9 ( 8.9) 2 ( 2.6) 0 (0.0) Nasopharyngitis 36 (32.1) 19 (18.8) 14 (18.2) 5 (27.8) Acne 28 (25.0) 8 ( 7.9) 3 ( 3.9) 0 (0.0) Headache 26 (23.2) 11 (10.9) 3 ( 3.9) 0 (0.0) Hypercholesterolemia 25 (22.3) 9 ( 8.9) 6 ( 7.8) 3 (16.7) Aphthous stomatitis 21 (18.8) 14 (13.9) 6 ( 7.8) 1 ( 5.6) Fatigue 19 (17.0) 2 ( 2.0) 2 ( 2.6) 0 (0.0) Cough 18 (16.1) 4 ( 4.0) 4 ( 5.2) 0 (0.0) Diarrhea 17 (15.2) 6 ( 5.9) 3 ( 3.9) 0 (0.0) Nausea 17 (15.2) 5 ( 5.0) 0 (0.0) 2 (11.1) Mouth ulceration 17 (15.2) 3 ( 3.0) 2 ( 2.6) 0 (0.0) Urinary tract infection 16 (14.3) 14 (13.9) 6 ( 7.8) 1 ( 5.6) Vomiting 15 (13.4) 7 ( 6.9) 1 ( 1.3) 1 ( 5.6) Hypertension 14 (12.5) 3 ( 3.0) 3 ( 3.9) 1 ( 5.6) Edema peripheral 12 (10.7) 8 ( 7.9) 4 ( 5.2) 0 (0.0) Amenorrhea 12 (10.7) 7 ( 6.9) 3 ( 3.9) 0 (0.0) Leukopenia 12 (10.7) 6 ( 5.9) 0 (0.0) 0 (0.0) Back pain 12 (10.7) 5 ( 5.0) 2 ( 2.6) 1 ( 5.6) Blood lactate dehydrogenase increased 12 (10.7) 2 ( 2.0) 1 ( 1.3) 0 (0.0) Hypophosphatemia 11 ( 9.8) 5 ( 5.0) 4 ( 5.2) 2 (11.1) 28
29 EXIST-2: Selected Adverse Events Infections (everolimus, 64.6%; placebo, 71.8%) Primarily upper respiratory infections (e.g., nasopharyngitis, upper respiratory tract infection) No cases of grade 4 infections were observed No Menstruation (everolimus, 13.5% [2 grade 3]); placebo, 3.8%) Duration ranged from 1 to 66 weeks, with no treatment modification in any cases 3 cases are ongoing in the everolimus arm; 4 resolved without intervention Renal events (everolimus, 5.1%; placebo, 15.4%) Included cases of grade 1-2 proteinuria, acute renal failure, and elevated creatinine There were 2 cases of grade 2 acute renal failure in the everolimus arm; both of these events resolved No patients with renal events had a prior nephrectomy EXIST-2; NCT Kingswood et al. International TSC Research Conference 2011 Bissler JJ et al. Lancet 2013; 381: SOL017E
30 Initiation of mtor Inhibitor Therapy in TSC-Associated Angiomyolipomas Use of mtor inhibitor therapy requires assessment of tolerance and side effect profile Follow-up of angiomyolipomas with MRI is required to assess response to therapy Consider referral to physician experienced with mtor inhibitor therapy Urologist Nephrologist (for renal angiomyolipoma) Neurologist (for SEGA) Oncologist 30
31 Surgery Should Not be Considered A First-Line Option Renal Embolization for TSC-associated Angiomyolipoma: Limitations Treats single lesions and not the full spectrum of disease (multiple small lesions) Due to variability in surgical techniques, outcomes are variable, with up to 40% requiring repeat embolization 1 Associated with post-embolization syndrome or perioperative complications (up to 85%) Risk of renal impairment with any invasive intervention Success, at the expense of: Loss of kidney mass/function Post-embolization syndrome 1. Bishay VL, et al. J Vasc Interv Radiol 2010;21:
32 Surgery Should Not be Considered A First-Line Option Full or Partial Nephrectomy Limitations: Associated with surgical morbidity/mortality Loss of renal function Risk of ischemic injury associated with this procedure Removal of kidney leaves less treatment options if angiomyolipoma develop in other kidney Bilateral growing lesions lead to loss of renal parenchyma This is not addressed by either nephrectomy or embolization Need therapy that will reduce angiomyolipoma volume, which may help to prevent hemorrhage, and preserve long-term renal function 32
33 Conclusions TSC is a multi-organ disease with potential for significant renal involvement TSC guidelines for diagnosis, surveillance and management are available Renal imaging, preferably MRI, can help reduce patient risk from haemorrhage Pharmacological therapy is available that treats not only the kidney but other aspects of TSC TSC may require the management of multiple specialists 33
34 34
35 35
36 Questions?
Diagnosing TSC by Making Clinical Connections
Diagnosing TSC by Making Clinical Connections TSC = tuberous sclerosis complex. Diagnosing tuberous sclerosis complex: MORE CLUES Definite Diagnosis of Tuberous Sclerosis Complex (TSC) Possible Diagnosis
More informationTuberous Sclerosis Complex
Tuberous Sclerosis Complex A successful transition from the bench to the bedside Mary Kay Koenig, MD The University of Texas Medical School at Houston Children s Memorial Hermann Hospital University of
More informationImaging of tuberous sclerosis complex
Imaging of tuberous sclerosis complex Poster No.: C-0388 Congress: ECR 2015 Type: Educational Exhibit Authors: M. V. Vu#kovi#, N. Menkovic, A. Petkovic, S. Ognjanovic, 1 2 1 1 1 1 1 1 J. Markov, M. Ilic,
More informationTeleconference on Tuberous Sclerosis Complex (TSC) Research October 28 th, 2008 and November 11 th, 2008
Wong 1 Teleconference on Tuberous Sclerosis Complex (TSC) Research October 28 th, 2008 and November 11 th, 2008 Sponsored by the Tuberous Sclerosis Alliance Faculty Participants: Elizabeth Henske, MD,
More informationClinical History. 29 yo woman with polyhydramnios Cardiac mass at fetal ultrasound At 35 weeks, newborn died 30 minutes after delivery
CASE 1 a Clinical History 29 yo woman with polyhydramnios Cardiac mass at fetal ultrasound At 35 weeks, newborn died 30 minutes after delivery Interface between tumor and normal myocardium Smaller well-demarcated
More informationPENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES (Proceed to Stage II) YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: TSC1, TSC2 DISORDER: Tuberous Sclerosis Complex (TSC) HGNC ID: 12362, 12363 OMIM ID: 191100, 613254 ACTIONABILITY 1. Is there a qualifying resource, such as
More informationHerczegfalvi Ágnes. Tuberous sclerosis. Case history. SE. II. sz. Gyermekklinika. Budapest, Febr
Herczegfalvi Ágnes Tuberous sclerosis Case history SE. II. sz. Gyermekklinika Budapest, Febr. 2016. Case history 1. GD. DOB: 05-03-1989 Pre and perinatal history: normal His development was normal till
More informationClinical Commissioning Policy Proposition: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
Clinical Commissioning Policy Proposition: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex Reference: NHS England E09X04/01 Information Reader Box (IRB)
More informationTuberous Sclerosis: New Treatment Strategies for an Old Disease
Tuberous Sclerosis: New Treatment Strategies for an ld Disease bjectives History and Diagnostic Criteria for Tuberous Sclerosis Darcy A. Krueger, M.D., Ph.D. Tuberous Sclerosis Clinic and Research Center
More informationEverolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery
Everolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery April 2011 This technology summary is based on information
More informationTuberous Sclerosis A Radiological Perspective
November 2001 Tuberous Sclerosis A Radiological Perspective Heather Brandling-Bennett, Harvard Medical School, Year III Tuberous Sclerosis Also referred to as Bourneville s disease or tuberous sclerosis
More informationCURIOSITY IS A LIFELONG CONDITION TOO
CURIOSITY IS A LIFELONG CONDITION TOO If you or a loved one has been diagnosed with tuberous sclerosis complex or TSC this booklet will help you get answers. It can also help if you think you may have
More informationPediatric Neurology 49 (2013) 255e265. Contents lists available at ScienceDirect. Pediatric Neurology
Pediatric Neurology 49 (2013) 255e265 Contents lists available at ScienceDirect Pediatric Neurology journal homepage: www. elsevier. com/ locate/ pnu Original Article Tuberous Sclerosis Complex Surveillance
More informationCURIOSITY IS A LIFELONG CONDITION TOO
CURIOSITY IS A LIFELONG CONDITION TOO If you or a loved one has been diagnosed with tuberous sclerosis complex or TSC this booklet will help you get answers. It can also help if you think you may have
More informationCASE REPORT. FAMILIAL TUBEROUS SCLEROSIS: A CASE REPORT M. Manjukeshwari 1, S. Chidambaranathan 2
FAMILIAL TUBEROUS SCLEROSIS: A M. Manjukeshwari 1, S. Chidambaranathan 2 HOW TO CITE THIS ARTICLE: M. Manjukeshwari, S. Chidambaranathan. Familial Tuberous Sclerosis: A Case Report. Journal of Evolution
More informationTuberous Sclerosis Complex A Review for Health Care Professionals
Renal Lesions in Patients With Tuberous Sclerosis Complex A Review for Health Care Professionals ONGOING SURVEILLANCE IS CRITICAL TO MONITOR THE PROGRESSION OFIntroduction KNOWN SYMPTOMS AND THE EMERGENCE
More informationEverolimus in the treatment of giant renal angiomyolipoma associated with tuberous sclerosis
CASE REPORT Advance Access publication 11 February 2016 Everolimus in the treatment of giant renal angiomyolipoma associated with tuberous sclerosis Miguel Oliveira 1, Marta Sofia Costa 1, Tiago Barra
More informationOpinion 20 March 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 March 2013 VOTUBIA 2.5 mg, tablet B/30 (CIP: 219 475-8) VOTUBIA 5 mg, tablet B/30 (CIP: 219 476-4) Applicant: NOVARTIS
More informationTuberous sclerosis with giant renal angiomyolipoma and sclerotic skeletal lesions in a geriatric patient: role of imaging
International Journal of Research in Medical Sciences Nagaraju RM et al. Int J Res Med Sci. 2015 Aug;3(8):2145-2149 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Case Report DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20150346
More informationTuberous Sclerosis Complex: Clinical overview
Tuberous Sclerosis Complex: Clinical overview Elizabeth A. Thiele, MD, PhD Director, Carol and James Herscot Center for Tuberous Sclerosis Complex Director, MGH Pediatric Epilepsy Program Professor of
More informationA Case Report on the Effect of Everolimus in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
Elmer Press Case Report A Case Report on the Effect of Everolimus in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex Huma M Paika a, d, Yull E. Arriaga b, Anthony Setiawan c Abstract Tuberous
More informationSWISS SOCIETY OF NEONATOLOGY. A rare cause of neonatal seizures
SWISS SOCIETY OF NEONATOLOGY A rare cause of neonatal seizures October 2006 2 Hagmann C, Robertson NJ, Centre for Perinatal Brain Research, Institute for Women s Health, University College London, London
More informationAssessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial
Cai et al. Orphanet Journal of Rare Diseases (2018) 13:43 https://doi.org/10.1186/s13023-018-0781-y RESEARCH Open Access Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous
More informationSupplementary Table 2. Surgical prophylaxis: Summary of selected series which included prophylactic management against the risk of bleeding.
Supplementary Tables of the article The Risks of Renal Angiomyolipoma: Reviewing the Evidence. Supplementary Table 2. Surgical prophylaxis: Summary of selected series which included prophylactic management
More informationTuberous sclerosis complex is a genetic
60 Journal of the association of physicians of india vol 62 december, 2014 Case Reports A Case Report of Tuberous Sclerosis in Two Generations Chandrakala *, Sharanagouda Patil **, KY Guruprasad *** Abstract
More informationTeen Talk TSC: An A-Z Guide to Living with Tuberous Sclerosis Complex (TSC) G-AFI
D Teen Talk TSC: An A-Z Guide to Living with Tuberous Sclerosis Complex (TSC) G-AFI-1087210 Living with a chronic disorder such as tuberous sclerosis complex (TSC) can be challenging for anyone teenagers
More informationApproach to the Genetic Diagnosis of Neurological Disorders
Approach to the Genetic Diagnosis of Neurological Disorders Dr Wendy Jones MBBS MRCP Great Ormond Street Hospital for Children National Hospital for Neurology and Neurosurgery What is a genetic diagnosis?
More informationEffects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report
Nephrology 22 (2016) (2017) 1017 1022 Original Article Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report JENG-DAU TSAI, 1,2 CHANG-CHING WEI, 3,4
More informationTuberous Sclerosis Complex: Rare Disease with Significant Social Impact (Case Series)
Original Articles 17 Tuberous Sclerosis Complex: Rare Disease with Significant Social Impact (Case Series) J. Breza jr. (Jan Breza jr.) 1, B. Novotna (Barbora Novotna) 2 Original Article 1 Department of
More informationCoexistence of Lymphangioleiomyomatosis and Angiomyolipomas in a Patient of Tuberous Sclerosis Complex: a case report
Chin J Radiol 2003; 28: 329-333 329 Coexistence of Lymphangioleiomyomatosis and Angiomyolipomas in a Patient of Tuberous Sclerosis Complex: a case report FENG-CHI HSIEH 1 KAO-LANG LIU 1 YIH-LEONG CHANG
More informationARTICLE. Keywords: TSC1 and TSC2; tuberous sclerosis complex; genotype phenotype correlation
(2005) 13, 731 741 & 2005 Nature Publishing Group All rights reserved 1018-4813/05 $30.00 www.nature.com/ejhg ARTICLE Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype phenotype
More informationIntroduction. Seyyed Hassan Tonekaboni MD 1, Parviz Tousi MD 2,
original ARTICLE Clinical and Para clinical Manifestations of Tuberous Sclerosis: A Cross Sectional Study on 81 Pediatric Patients How to Cite this Article: Tonekaboni SH, Tousi P, Ebrahimi A, Ahmadabadi
More informationEarly diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?
Słowińska et al. Orphanet Journal of Rare Diseases (2018) 13:25 DOI 10.1186/s13023-018-0764-z RESEARCH Open Access Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis
More informationContents. TSC and kidneys. P3 Introduction P4 Monitoring P5 Renal (kidney) AMLs P7 Renal (kidney) cysts P8 Information and support
TSC and kidneys Contents TSC and kidneys P3 Introduction P4 Monitoring P5 Renal (kidney) AMLs P7 Renal (kidney) cysts P8 Information and support P2 Introduction Tuberous sclerosis complex (TSC) is a rare
More informationSPR 2 nd Pediatric Body MRI Course MRI and Oncology Sunday, September 17, SAM Reference Document
SPR 2 nd Pediatric Body MRI Course MRI and Oncology Sunday, September 17, 2017 SAM Reference Document Radiology Diagnostic Confidence in Oncology, an Oncologist s Perspective James Geller, MD 1. Goals
More informationCauses of mortality in individuals with tuberous sclerosis complex
DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY ORIGINAL ARTICLE Causes of mortality in individuals with tuberous sclerosis complex SAM AMIN 1 ANDREW LUX 1 NUALA CALDER 2 MATTHEW LAUGHARNE 3 JOHN OSBORNE 2 FINBAR
More informationWhat I know best: Tuberous Sclerosis Complex
What I know best: Tuberous Sclerosis Complex Prof Petrus de Vries Sue Struengmann Professor of Child & Adolescent Psychiatry University of Cape Town South Africa Red Cross War Memorial Children s Hospital,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 4 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 January 2012 VOTUBIA 2.5 mg, tablet B/30 (CIP code: 219 475-8) VOTUBIA 5 mg, tablet B/30 (CIP code: 219 476-4) Applicant:
More informationUroradiology For Medical Students
Uroradiology For Medical Students Lesson 8 Computerized Tomography 2 American Urological Association Objectives In this lesson you will: Gain more experience reading CT images Learn how computer generated
More informationCommon Drug Review Clinical Review Report
Common Drug Review Clinical Review Report September 2017 Drug everolimus (Afinitor) (oral tablets) Indication For the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with
More informationTuberous sclerosis complex (TSC) is an autosomal dominant
Winter/Spring 2018 A Look at the Genetics of TSC: How Important Is Genetic Testing to Patients and Their Physicians? About TSC Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder
More informationPediatric Retroperitoneal Masses Radiologic-Pathologic Correlation
Acta Radiológica Portuguesa, Vol.XVIII, nº 70, pág. 61-70, Abr.-Jun., 2006 Pediatric Retroperitoneal Masses Radiologic-Pathologic Correlation Marilyn J. Siegel Mallinckrodt Institute of Radiology, Washington
More informationeuropean journal of paediatric neurology 20 (2016) 296e308 Official Journal of the European Paediatric Neurology Society
european journal of paediatric neurology 20 (2016) 296e308 Official Journal of the European Paediatric Neurology Society Original article The clinical profile of tuberous sclerosis complex (TSC) in the
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Case Report Everolimus: Paradigm Shift in the Management of Tuberous Sclerosis Dr Sabarish Mahalingam 1, Dr P. Z. Wadia
More informationTuberous Esclerosis in different organs
Tuberous Esclerosis in different organs Poster No.: C-1325 Congress: ECR 2013 Type: Educational Exhibit Authors: T. Gamo Jiménez, I. Martin, I. Millán Arredondo, E. Serrano 1 2 2 2 2 2 2 Tamayo, C. García
More informationRenal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors
http://www.kidney-international.org & 2006 International Society of Nephrology original article Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors SK Rakowski
More informationTuberous sclerosis: evaluation of intracranial lesions
Neuroradiology/Pictorial Essay Tuberous sclerosis: evaluation of intracranial lesions J. Docampo*, M. Cabrini, C. Bruno and C. Morales. Fundación Científica del Sur, Lomas de Zamora, Province of Buenos
More informationBilateral Angiomyolipama of the kidneys with shock due to rupture: Can conservative management be an option?
2017 Academic Web Journal of Medical Science Volume 2 issue 2 pp 024-029 May, 2017 ISSN: 2545-4986 Accepted 31 st May, 2017 Case Report Bilateral Angiomyolipama of the kidneys with shock due to rupture:
More informationUniversity of Cape Town
Pilot validation of the Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) Checklist as a screening tool for neuropsychiatric manifestations By Loren Leclezio LCLLOR001 SUBMITTED TO THE UNIVERSITY
More informationNeurocutaneous Syndromes. Phakomatoses
Neurocutaneous Syndromes Phakomatoses Financial Disclosures I have NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT Neurocutaneous Syndomes Definition Entities Diagnosis/ Presentation
More informationSPETRUM OF ABDOMINAL IMAGING FINDINGS IN TUBEROUS SCLEROSIS: The common and uncommon manifestations.
SPETRUM OF ABDOMINAL IMAGING FINDINGS IN TUBEROUS SCLEROSIS: The common and uncommon manifestations. Poster No.: C-925 Congress: ECR 204 Type: Educational Exhibit Authors: J. B. Dutra, A. F. D. Melo, E.
More informationTuberous Sclerosis Alliance and Tuberous Sclerosis Complex Clinics Scope of Relationship Policy
Tuberous Sclerosis Alliance and Tuberous Sclerosis Complex Clinics Scope of Relationship Policy ROLE OF THE TSC CLINIC A Tuberous Sclerosis Complex (TSC) Clinic is defined as a group of board-certified
More informationNeurocutaneous Disorders NEUROFIBROMATOSIS 11/1/2012 NEUROFIBROMATOSIS TYPE1 GENETICS. NEUOFIBROMATOSIS type 1 Cutaneous Manifestations
Neurocutaneous Disorders M Ammar Katerji, MD NEUROFIBROMATOSIS STURGE WEBER SYNDROME INCONTINENTIA PIGMENTI INCONTINENTIA PIGMENTI ACHROMIANS LINEAR SEBACEOUS NEVUS NEVUS UNIS LATERIS KLIPPEL-TRENAUNAY-WEBER
More informationPharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension)
Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension) Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management
More informationHepatic manifestations of tuberous sclerosis complex: a genotypic and phenotypic analysis
Clin Genet 2012: 82: 552 557 Printed in Singapore. All rights reserved Short Report 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd CLINICAL GENETICS doi: 10.1111/j.1399-0004.2012.01845.x
More informationUrinary tract embolization
Beograd, 14.10.2012 Urinary tract embolization asist. Peter Popovič, MD, MSc Head of abdominal radiology department, Institute of Radiology, UMC Ljubljana Embolization Who and when procedure: local/general
More informationPatient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
More informationGeneral History. Sex : female Birth Date : 68 / 02 /10 Date of Admission : 91 /08 / 04
General History Sex : female Birth Date : 68 / 02 /10 Date of Admission : 91 /08 / 04 Chief Complain Epigastric pain with bloody vomitus for 1 day Present Illness This 22 year-old girl is a case of tuberous
More informationThese are the learning objectives for our time and for the discussion today.
Moderator: Good day, everyone, and welcome. On behalf of AXIS Medical Education, I would like to welcome you to our educational event today entitled, Overcoming Treatment Challenges for Tuberous Sclerosis
More informationLiving with rare lung disease LYMPHANGIOLEIOMYOMATOSIS (LAM): The Patient Perspective. Gill Hollis, Edinburgh January 2010
Living with rare lung disease LYMPHANGIOLEIOMYOMATOSIS (LAM): The Patient Perspective Gill Hollis, Edinburgh January 2010 LAM Basics Disease of the lungs and lymphatics Affects women Causes progressive
More informationBilateral Renal Angiomyolipomas with Invasion of the Renal Vein: A Case Report
Case Study TheScientificWorldJOURNAL (2008) 8, 145 148 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2008.29 Bilateral Renal Angiomyolipomas with Invasion of the Renal Vein: A Case Report C. Blick, N. Ravindranath,
More informationTuberous sclerosis complex (TSC) involves multiple
Case Report 696 Concurrent Hepatic and Ruptured Renal Angiomyolipoma in Tuberous Sclerosis Complex Cheng-Han Chao, MD; Chin-Yew Lin 1, MD; Siu-Cheung Chan 2, MD; Kuo-Su Chen 3, MD Angiomyolipoma of the
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION EVEROLIMUS (Afinitor Novartis Pharmaceuticals Canada) Indication: Renal Angiomyolipoma Associated with Tuberous Sclerosis Complex Recommendation: The Canadian Drug Expert Committee
More informationCLINICAL AND PRE CLINICAL STUDIES OF RENAL DISEASE IN TUBEROUS SCLEROSIS. Anna Hellmann Thamann
CLINICAL AND PRE CLINICAL STUDIES OF RENAL DISEASE IN TUBEROUS SCLEROSIS By Anna Hellmann Thamann A thesis submitted in candidature for the degree of Master of Philosophy 2014 Department of Medical Genetics
More informationFAQ Identifying and enrolling participants
FAQ Identifying and enrolling participants WHO IS ELIGIBLE - CASES? Patients with a new diagnosis of primary systemic vasculitis Patients suitable as cases are over 18 years with a new presentation or
More informationThe effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma
Pediatr Nephrol (2018) 33:101 109 DOI 10.1007/s00467-017-3806-1 ORIGINAL ARTICLE The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal
More informationTuberous sclerosis presenting as atypical aggressive retinal astrocytoma with proliferative retinopathy and vitreous haemorrhage
Case Report Brunei Int Med J. 2015; 11 (1): 49-53 Tuberous sclerosis presenting as atypical aggressive retinal astrocytoma with proliferative retinopathy and vitreous haemorrhage Pui Ling TANG and Mae-Lynn
More informationRecurrent Pediatric UTI Revisited 2013
Recurrent Pediatric UTI Revisited 2013 PIDSP 21.2.2013 Shai Ashkenazi, MD, MSc Medicine changes constantly Some aspects of the standard practice of ~40 years are probably not valid and need to be changed
More informationEarly detection of Retinoblastoma in children. Max Mantik
Early detection of Retinoblastoma in children Max Mantik Introduction The most common primary intraocular malignancy of childhood 10 to 15 % of cancers that occur within the first year of life Typical
More informationGuidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationUNLOCKING A CURE FOR TUBEROUS SCLEROSIS COMPLEX. An Assessment of Scientific Progress and Research Needs
UNLOCKING A CURE FOR TUBEROUS SCLEROSIS COMPLEX An Assessment of Scientific Progress and Research Needs A White Paper by: Vicky Holets Whittemore, PhD 801 Roeder Road, Suite 750 Silver Spring, MD 20910
More informationOptimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review
641353TAU0010.1177/1756287216641353Therapeutic Advances in UrologyJJ Bissler and JC Kingswood research-article2016 Therapeutic Advances in Urology Review Optimal treatment of tuberous sclerosis complex
More informationEfficacy and safety of Everolimus in children with TSC - associated epilepsy Pilot data from an open single-center prospective study
Samueli et al. Orphanet Journal of Rare Diseases (2016) 11:145 DOI 10.1186/s13023-016-0530-z RESEARCH Efficacy and safety of Everolimus in children with TSC - associated epilepsy Pilot data from an open
More informationCase 7391 Intraventricular Lesion
Case 7391 Intraventricular Lesion Bastos Lima P1, Marques C1, Cabrita F2, Barbosa M2, Rebelo O3, Rio F1. 1Neuroradiology, 2Neurosurgery, 3Neuropathology, Coimbra University Hospitals, Portugal. University
More informationGUIDELINES ON RENAL CELL CANCER
20 G. Mickisch (chairman), J. Carballido, S. Hellsten, H. Schulze, H. Mensink Eur Urol 2001;40(3):252-255 Introduction is characterised by a constant rise in incidence over the last 50 years, with a predominance
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationBenefits and Risks of Cancer Imaging
Benefits and Risks of Cancer Imaging Jeffrey T. Yap, PhD http://catalyst.harvard.edu/ services/imagingconsulting.html Senior Diagnostic Physicist, Department of Imaging, DFCI Assistant Professor of Radiology,
More informationPrenatal Prediction of The Neurologically Impaired Neonate By Ultrasound
Prenatal Prediction of The Neurologically Impaired Neonate By Ultrasound Robert H. Debbs, D.O.,F.A.C.O.O.G. Professor of OB-GYN Perelman School of Medicine, University of Pennsylvania Director, Pennsylvania
More informationConsistent localisation of interictal epileptiform activity on EEGs of patients with tuberous sclerosis complex
Consistent localisation of interictal epileptiform activity on EEGs of patients with tuberous sclerosis complex 5 Consistent localisation of interictal epileptiform activity on EEGs of patients with tuberous
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRegulatory Affairs. Afinitor (Everolimus)
Regulatory Affairs Afinitor (Everolimus) Summary of the Risk Management Plan (RMP) for Afinitor (Everolimus) Reference RMP EU RMP version 13.0/13.0 Products concerned (brand names): Afinitor and Votubia
More informationYear 2003 Paper two: Questions supplied by Tricia
question 43 A 42-year-old man presents with a two-year history of increasing right facial numbness. He has a history of intermittent unsteadiness, mild hearing loss and vertigo but has otherwise been well.
More informationCanadian Urological Association guidelines for followup of patients after treatment of nonmetastatic
Canadian Urological Association guidelines for followup of patients after treatment of nonmetastatic renal cell carcinoma Wassim Kassouf, Leonardo L. Monteiro, Darrel E. Drachenberg, Adrian S. Fairey,
More informationTuberous sclerosis complex without tubers and subependymal nodules: a phenotype genotype study
Clin Genet 2014: 86: 149 154 Printed in Singapore. All rights reserved Short Report 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd CLINICAL GENETICS doi: 10.1111/cge.12245 Tuberous sclerosis
More informationProfessor Suetonia Palmer
Professor Suetonia Palmer Department of Medicine Nephrologist Christchurch Hospital Christchurch 14:00-14:55 WS #108: The Kidney Test - When To Test and When to Refer ( and When Not To) 15:05-16:00 WS
More informationNEURORADIOLOGY-NEUROPATHOLOGY CONFERENCE
THE UNIVERSITY OF NORTH CAROLINA at CHAPEL HILL SEPTEMBER 2013 NEURORADIOLOGY-NEUROPATHOLOGY CONFERENCE Claudia da Costa Leite, MD, PhD Thomas Bouldin, MD CASE 1 6 y-o female with headaches and vomiting
More informationAngiomyolipomas: Miles Mannas David Liu MD FRCPC FSIR UBC Departments of Urologic Sciences and Radiology June 8, 2016 OBJECTIVES
Angiomyolipomas: Current evidence and its effect on management Miles Mannas David Liu MD FRCPC FSIR UBC Departments of Urologic Sciences and Radiology June 8, 2016 OBJECTIVES Epidemiology & Etiology Presentation
More informationPediatric Brain Tumors Pre, Intra & Post Op Evaluation and Management. Timothy M. George, MD, FACS, FAAP
Pediatric Brain Tumors Pre, Intra & Post Op Evaluation and Management Timothy M. George, MD, FACS, FAAP PEDIATRIC BRAIN TUMORS BACKGROUND: Incidence: Third most common pediatric tumor type (leukemia, neuroblastoma,
More informationASSOCIATION LUPUS AND TUBEROUS SCLEROSIS: IS IT POSSIBLE? THE INVOLVEMENT OF MTOR PATHEWAY
wjpmr, 2017,3(6), 76-80 SJIF Impact Factor: 4.103 Rahima et al. Research Article WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH ISSN 2455-3301 www.wjpmr.com WJPMR ASSOCIATION LUPUS AND TUBEROUS SCLEROSIS:
More informationWE RE IN A CONSTANT STRUGGLE. BUT WITH AFINITOR, WE VE FOUND ANOTHER OPTION.
SEGA TSC Novartis Pharmaceuticals Corporation is committed to supporting individuals affected by SEGA with TSC through therapeutic innovation, patient assistance, and support of advocacy organizations.
More informationSELF-ASSESSMENT MODULE REFERENCE SPR 2018 Oncologic Imaging Course Adrenal Tumors November 10, :00 12:10 p.m.
SELF-ASSESSMENT MODULE REFERENCE SPR 2018 Oncologic Imaging Course Adrenal Tumors November 10, 2018 10:00 12:10 p.m. Staging Susan E. Sharp, MD 1. In the International Neuroblastoma Risk Group Staging
More informationSAMPLING OF POST NEPHRECTOMY CANCER CARE (5)
SAMPLING OF POST NEPHRECTOMY CANCER CARE (5) Universally recognized post-nephrectomy cancer treatment. Sampling: National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidelines in Oncology
More informationConvulsive Disorder and Cardiac Disease. Running Rachael, Active Ashlee, Sassy Savannah
Convulsive Disorder and Cardiac Disease Running Rachael, Active Ashlee, Sassy Savannah Convulsive Disorder Seizure is over. Pay attention to how long the seizure lasts. Stay calm. Make the person as comfortable
More informationIs renal cryoablation becoming an effective alternative to partial nephrectomy?
Is renal cryoablation becoming an effective alternative to partial nephrectomy? J GARNON 1, G TSOUMAKIDOU 1, H LANG 2, A GANGI 1 1 department of interventional radiology 2 department of urology University
More informationAuthor(s) Gohji, Kazuo; Gotoh, Akinobu; Kamid. Citation 泌尿器科紀要 (1990), 36(7):
Title Giant renal angiomyolipoma with an pattern: a case report Author(s) Gohji, Kazuo; Gotoh, Akinobu; Kamid Citation 泌尿器科紀要 (1990), 36(7): 837-840 Issue Date 1990-07 URL http://hdl.handle.net/2433/116942
More informationPediatric Abdominal Masses. Andrew Phelps MD Assistant Professor of Pediatric Radiology UCSF Benioff Children's Hospital
Pediatric Abdominal Masses Andrew Phelps MD Assistant Professor of Pediatric Radiology UCSF Benioff Children's Hospital No Disclosures Take Home Message All you need to remember are the 5 common masses
More information